Company Profile

Visx Inc
Profile last edited on: 2/16/22      CAGE:       UEI:

Business Identifier: Laser vision correction systems
Year Founded
1986
First Award
1991
Latest Award
1994
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3400 Central Expressway
Santa Clara, CA 95051
   (408) 733-2020
   N/A
   www.visx.com
Location: Single
Congr. District: 17
County: Santa Clara

Public Profile

In May 2005 VISX Inc was acquired by Advanced Medical Optics (AMO). VISX, Incorporated is in the development of proprietary technologies and systems for laser vision correction (LVC), which relies on a computerized laser to treat nearsightedness, astigmatism and farsightedness with the goal of eliminating or reducing reliance on eyeglasses and contact lenses. The VISX Excimer Laser System is a fully integrated medical device incorporating an excimer laser and a computer-driven workstation. The VISX System removes submicron layers of tissue from the surface of the cornea to reshape the eye so that images are properly focused on the retina, which in turn reduces or eliminates the need for corrective eyewear. The VISX System is also designed to treat certain types of corneal pathologies in an outpatient procedure known as PhotoTherapeutic Keratectomy or PTK. In addition to marketing the VISX System, the Company supplies proprietary optical memory cards, called VisionKey, which are sold separately and control the use of the VISX System.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NYSE : EYE
IP Holdings
150-249

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1994 2 NIH $601,496
Project Title: Therapeutic Correction of Hyperopia with Excimer Photorefractive Keratectomy (PRK)
1993 2 NIH $549,439
Project Title: Therapeutic Correction of Astigmatism with Excimer PRK

Key People / Management

  Elizabeth H Davila -- President

  Charles R Munnerlyn

  William B Telfair

Company News

There are no news available.